Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Tony K. Choueiri*, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M. Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy KopyltsovAjjai Alva, Stephane Oudard, Delphine Topart, Hans Hammer, Hiroshi Kitamura, David F. McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science